Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells (2008)

Peer-Reviewed Study · Doudican N; Rodriguez A; Osman I; Orlow SJ · July 30, 2008

Doudican N et al., 2008-07-30: A screen of 2,000 compounds in chemoresistant melanoma lines that surfaced four benzimidazoles, with mebendazole pursued because of its pharmacokinetics; it inhibited melanoma growth at an average IC50 of 0.32 micromolar and acted through Bcl-2 phosphorylation. It is the paper that ties mebendazole's cancer activity to a specific apoptotic mechanism.

We identified 10 compounds that inhibited the growth of the melanoma cells yet were largely nontoxic to melanocytes. Strikingly, 4 of the 10 compounds (mebendazole, albendazole, fenbendazole, and oxybendazole) are benzimidazoles, a class of structurally related, tubulin-disrupting drugs.

abstract

Doudican N et al., 2008-07-30: A screen of 2,000 compounds in chemoresistant melanoma lines that surfaced four benzimidazoles, with mebendazole pursued because of its pharmacokinetics; it inhibited melanoma growth at an average IC50 of 0.32 micromolar and acted through Bcl-2 phosphorylation. It is the paper that ties mebendazole's cancer activity to a specific apoptotic mechanism. Study type: cell-line drug screen plus mechanistic work (preclinical). N: three cell lines (M-14, SK-Mel-19 melanoma; melan-a immortalised melanocytes), 2,000-compound Spectrum Library at 1 micromolar. Country: United States (NYU School of Medicine). Dose: 1 micromolar screen; IC50 0.32 micromolar. Funder/conflicts: not stated in the abstract; full text paywalled and not read. Product: laboratory compound from the Spectrum Library (not a commercial brand). Comparator: non-tumorigenic melanocyte line. Same screen found fenbendazole and albendazole active, which is relevant to the fenbendazole claims handled in other runs. Also filed as MBB-25 (claims C3, C7). Study type: lab.